explore -WSS

explore

author：fashion 2025-10-01 00:59:15 - browse：94

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

entertainment

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Morphosys mixed study results for blood cancer drug

Childhood cancer progress stalls for Black, Hispanic kids: Report

FDA's Woodcock to retire early next year

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Sports medicine is finally prioritizing gender equality

PBM reforms clear House panel

Medical leaders decry Supreme Court decision on affirmative action

A daunting task: navigating dual Medicare, Medicaid eligibility

ChatGPT in medicine: STAT answers readers' burning questions

Hospitals look to new technology to keep health care workers safe

Psychedelics group wrestles with new pharma identity

Ransomware attacks on hospitals: Study outlines patient impact

Medical leaders decry Supreme Court decision on affirmative action

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

NYU radiologists take on the challenge of expensive MRI machines

Congress must reauthorize a committee to support older Americans

Why medical students are struggling with mental health

Hospitals look to new technology to keep health care workers safe

A daunting task: navigating dual Medicare, Medicaid eligibility

World's first CRISPR

entertainment

explore

entertainment

explore